Brief: Beyondspring Announces U.S. FDA Acceptance And Priority Review Of New Drug Application For Plinabulin And G-Csf Combination For The Prevention Of Chemotherapy-Induced Neutropenia (Cin)
01/06/2021 14:33
June 1 (Reuters) - Beyondspring Inc BYSI.O :
* BEYONDSPRING ANNOUNCES U.S. FDA ACCEPTANCE AND PRIORITY
REVIEW
OF NEW DRUG APPLICATION FOR PLINABULIN AND G-CSF COMBINATION FOR
THE PREVENTION OF CHEMOTHERAPY-INDUCED NEUTROPENIA (CIN)
* BEYONDSPRING INC - FDA HAS SET A PDUFA TARGET ACTION DATE
FOR
NOVEMBER 30, 2021
Source text for Eikon: ID:nGNX58PZmB
Further company coverage: BYSI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beyondspring
See all newsBrief: Beyondspring Inc Entered Into Open Market Sale Agreement Under Which Co May Offer And Sell Up To 9.2 Million Ordinary Shares
Brief: Beyondspring Announces FDA Fast Track Designation For Plinabulin In Post-Ici Non-Squamous Nsclc And Strategic Transaction To Advance Global Phase 3 Dublin-4 Trial Toward Planned Interim Analysis
NASDAQ RESUMED AT 12:26 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:21 PM
Brief: Beyondspring Announces Leadership Transition To Deliver Focused Execution On Its Confirmatory Dublin-4 Program And Long-Term Value